Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7948552 | 0.92 | CA1 (0.64) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL24983914 | 0.92 | CA1 (0.64) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL7940922 | 0.92 | CA1 (0.64) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL24090327 | 0.92 | CA1 (0.64) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL7948565 | 0.92 | CA1 (0.64) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL18268944 | 0.92 | CA1 (0.50) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL18268926 | 0.92 | CA1 (0.50) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL6286442 | 0.88 | CA1 (0.58) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL6288619 | 0.88 | CA1 (0.58) | CA1CA9KMT2ACA2CA4 | |
| SCHEMBL4671527 | 0.86 | CA1 (0.50) | CA1CA9KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257663-A1 | FOOD CONTACT SURFACE SANITIZING LIQUID | The Procter & Gamble Company (US) | 2023-10-11 | — | — | EP | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| EP-4257663-A1 | FOOD CONTACT SURFACE SANITIZING LIQUID | The Procter & Gamble Company (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3416729-B1 | PRO-FRAGRANCE COMPOSITION | AQDOT LTD (GB) | 2023-09-20 | — | — | EP | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220386600-A1 | ANTIMICROBIAL COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2022-12-08 | — | — | US | disclosed |
| EP-4098121-A1 | ANTIMICROBIAL COMPOSITION | The Procter & Gamble Company (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | SENOMYX INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20130017582-A1 | ENHANCED PRODUCTION OF TAXOL AND TAXANES BY CELL CULTURES OF TAXUS SPECIES | PHYTON HOLDINGS, LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-8338143-B2 | Enhanced production of paclitaxel and taxanes by cell cultures of Taxus species | PHYTON HOLDINGS, LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110086397-A1 | ENHANCED PRODUCTION OF TAXOL AND TAXANES BY CELL CULTURES OF TAXUS SPECIES | PHYTON HOLDINGS, LLC (US) | 2011-04-14 | — | — | US | disclosed |
| US-20080108115-A1 | ENHANCED PRODUCTION OF TAXOL AND TAXANES BY CELL CULTURES OF TAXUS SPECIES | DFB BIOTECH, INCORPORATED (US) | 2008-05-08 | — | — | US | disclosed |
| US-7264951-B1 | Enhanced production of taxol and taxanes by cell cultures of Taxus species | PHYTON, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-0954596-B1 | ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF TAXUS SPECIES | PHYTON INC (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1538214-A1 | Enhanced production of taxanes by cell cultures of taxus species | PHYTON, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1398384-A1 | Enhanced production of taxanes by cell cultures of taxus species | Phyton Inc. (US) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CA1 1475/4885CA9 1234/4885KMT2A 2697/4885 |
| US-20160376263-A1 | BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF | TAS2R5, TAS1R1, TAS2R1 | CA1 3404/4885CA9 2662/4885KMT2A 2214/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CA1 1475/4885CA9 1234/4885KMT2A 2697/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CA1 1475/4885CA9 1234/4885KMT2A 2697/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CA1 1475/4885CA9 1234/4885KMT2A 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.